H2SITE and SNAM Collaborate on an Innovative Hydrogen and Natural Gas Separation Project Promoted by ARERA
H2SITE, a leading company in hydrogen separation technology and hydrogen transportation solutions, has announced its collaboration with SNAM, one of Europe’s key energy infrastructure operators, to develop an innovative project focused on the separation of hydrogen and natural gas mixtures.
As part of this initiative, H2SITE has designed a Pd-alloy membrane separator, capable of extracting hydrogen from 2% to 10% concentrations. Once built, this unit will represent the largest installation of its kind, capable of separating hydrogen at low concentrations while achieving high recovery rates.
The Pd-alloy membrane separator allows the recovered hydrogen to be used directly in fuel cells, hydrogen-to-power solutions such as gas turbines and engines, and high-temperature ovens. At the same time, it minimizes the hydrogen content in the remaining natural gas, preventing unwanted alterations in its composition. This is particularly important for industrial consumers whose processes cannot tolerate significant hydrogen concentrations and ensures compliance with local regulations in the gas grid. H2SITE membranes will operate at pressures above 50 bar, an industrial scale proof point relevant for large-scale hydrogen storage applications, such as salt caverns or depleted reservoirs.
H2SITE’s hydrogen separation technology has already been successfully validated with gas distribution grid operators, demonstrating the compatibility of existing distribution infrastructures with the transport of hydrogen-natural gas mixtures. It has also proven the efficient separation of hydrogen from the natural gas stream, enabling both the production of high-purity hydrogen and the removal of hydrogen from natural gas while maintaining to clean streams.
This new project reinforces H2SITE’s strategic collaboration with major infrastructure players like transmission system operators (TSOs), distribution system operators (DSOs), and other stakeholders interested in hydrogen separation. Additionally, and thanks to the support from the Italian Regulatory Authority for Energy, Networks, and Environment (ARERA), it strengthens H2SITE’s commercial presence in the Italian market, fostering collaborations and promoting the adoption of innovative technologies for the energy transition.
This initiative marks a significant step towards decarbonizing the energy sector, leveraging existing infrastructure, such as pipelines, and integrating new ones, such as salt caverns etc. to facilitate hydrogen integration as a clean and renewable energy source. Through advanced separation solutions, H2SITE and SNAM are contributing to making hydrogen a key resource for the future of sustainable energy.
About H2SITE
H2SITE, founded in 2020, is a technology company specializing in the on-site production and separation of high-purity hydrogen. The company utilizes exclusive palladium-alloy membrane reactor technology to efficiently convert various feedstocks—including ammonia, methanol, and syngas—into hydrogen. Additionally, H2SITE enables the separation of hydrogen from low-concentration gaseous mixtures for applications such as salt caverns or geologic hydrogen. By decentralizing hydrogen production through innovative ammonia cracking and separation solutions, H2SITE addresses the challenges of cost-effective hydrogen transportation and storage, significantly reducing associated costs and emissions.
About SNAM
SNAM is a leading European operator in gas infrastructure, specialized in Transportation, with a network exceeding 38,000 km across Italy and abroad; in Storage, holding one-sixth of the European Union's entire storage capacity; and in Regasification, where it ranks as the third largest European player, managing (or co-managing) an estimated annual capacity of 28 billion cubic metres, including the Ravenna LNG plant. SNAM's long-term ambition is to develop energy infrastructure for a sustainable future, positioning itself as a multi-molecule operator at both national and European levels. The company prioritizes transformative innovation and all-round sustainability as its key strategic levers, enhancing the role of gas as a transition vector. SNAM is among the top listed Italian companies by market capitalisation and is committed to continuous growth in sustainable finance.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250316570861/en/
Contacts
For more information:
Andrés Galnares, CEO of H2SITE:
andres.galnares@h2site.eu
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
www.businesswire.com

Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Daiichi Sankyo Announces the Initiation of the Development of Oral Triple Combination Lipid-Lowering Tablets to Support the Management of LDL-C30.8.2025 19:00:00 EEST | Press release
Daiichi Sankyo Europe is pleased to announce the initiation of the development of new oral triple combination tablets in Europe of bempedoic acid, ezetimibe, and different doses of a statin (atorvastatin or rosuvastatin), with the potential to lower low-density lipoprotein cholesterol (LDL-C) levels.9 It is well known that combination therapies reduce the pill burden for patients, potentially enhancing treatment adherence and facilitating treatment with a goal of improving cardiovascular outcomes.9,10 “As bempedoic acid and ezetimibe are already approved as a single-dose therapy, the development of an oral triple combination tablet with different doses of a statin, can make it easier for physicians to tailor treatment to the individual needs of each patient,” says Dr. Stefan Seyfried, Vice President and Head Medical Affairs Specialty Medicines, Daiichi Sankyo Europe. “This approach exemplifies our dedication to our motto: ‘we care for every heartbeat’.” “The management of dyslipidaemia
Alnylam to Advance Zilebesiran into Global Phase 3 Cardiovascular Outcomes Trial30.8.2025 17:30:00 EEST | Press release
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced plans to initiate a Phase 3 cardiovascular outcomes trial (CVOT) to evaluate the potential of zilebesiran to reduce the risk of major adverse cardiovascular events. This decision is informed by results from the comprehensive KARDIA Phase 2 program, including KARDIA-3 results presented today as a late-breaking abstract at the European Society of Cardiology (ESC) Congress in Madrid, Spain. Zilebesiran is an investigational subcutaneously administered RNAi therapeutic which, in the KARDIA Phase 2 program, has shown reductions in blood pressure by targeting liver-expressed angiotensinogen (AGT), the most upstream precursor in the Renin-Angiotensin-Aldosterone System (RAAS), which plays a key role in blood pressure regulation and impacts cardiovascular and renal health. KARDIA-3, the third Phase 2 study in the KARDIA program, evaluated the efficacy and safety of zilebesiran in patients with
BeOne Medicines Announces Positive Topline Results for Sonrotoclax in Relapsed or Refractory Mantle Cell Lymphoma (MCL)29.8.2025 13:00:00 EEST | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced positive topline results from a Phase 1/2 study (BGB-11417-201) of sonrotoclax, a next-generation and potentially best-in-class investigational BCL2 inhibitor, in adult patients with relapsed/refractory (R/R) mantle cell lymphoma (MCL), following treatment with a Bruton’s tyrosine kinase inhibitor (BTKi) and anti-CD20 therapy. BeOne plans to present the full data at an upcoming medical meeting. “For people with relapsed or refractory mantle cell lymphoma, the disease is aggressive, the treatment landscape fragmented, and the outcomes unacceptably poor. These topline results for sonrotoclax underscore its potential to deliver meaningful and durable responses and offer the first BCL2 inhibitor for patients with R/R MCL, if approved,” said Lai Wang, PhD, Global Head of R&D, BeOne Medicines. “These data add to the remarkable progress we’ve seen over the past five years in treating B-cel
Oulu2026 – European Capital of Culture: Oulu to Unveil Full European Capital of Culture 2026 Programme – Live Stream on 4 September 202529.8.2025 11:46:00 EEST | Press release
Hundreds of partners are creating a year in which Northern Finland becomes a new hub of culture. The programme will offer something for everyone: large-scale exhibitions, festivals across all genres, world premieres, performing arts, village celebrations, permanent artworks, sports, and community events across a vast region of 40 municipalities. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250829591577/en/ Oulu, with its 39 partner municipalities in Northern Finland, will step into the spotlight as European Capital of Culture 2026. The full programme will be officially launched on Thursday 4 September 2025 in Oulu, streamed live across Europe. The Oulu2026 programme is built around the theme of Cultural Climate Change, meaning a lasting enrichment of cultural life – connecting people through world-class experiences, creativity, and new ways of thinking. “2026 will be a transformative year – for our city, for Northern Finla
Nippon Sanso Holdings Group Unifies Global Brand Logo Launching the "NIPPON SANSO" Brand Worldwide29.8.2025 09:00:00 EEST | Press release
Nippon Sanso Holdings Corporation (President CEO: Toshihiko Hamada) will unify the brand logo for its industrial gas business globally and implement the change in stages. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250828253560/en/ Until now, our group has operated industrial gas businesses worldwide using the same symbol mark, while adapting to each region. To further enhance recognition and understanding of our group as a unified entity among a broad range of stakeholders, and to maximize corporate value and achieve sustainable growth, we have decided to unify the brand for our industrial gas businesses as "NIPPON SANSO" and standardize the brand logo globally. Moving forward, we will continue striving to be a trusted company for all stakeholders as a globally recognized brand. *Please note that Thermos Group, which operates the consumer household goods business within our group, will not change its brand logo. *The log
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom